News | News By Subject | News by Disease News By Date | Search News

Leukemia [Acute myelogenous leukemia (AML)] News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Patient Dies in Cellectis (CLLS)' Groundbreaking CAR-T Trial, Forcing a Halt to Trials     9/11/2017
Jazz Pharma (JAZZ) Bets $175 Million on This Massachusetts Biotech's Antibody-Drug Program     8/29/2017
Agios (AGIO), Celgene (CELG) Win Early FDA Approval for New Cancer Drug     8/3/2017
FDA Calls Roche (RHHBY)'s Leukemia Drug a Breakthrough     7/31/2017
Seattle Genetics (SGEN) Takes Another Hit as the FDA Slaps Hold on IND for Vadastuximab Talirine     6/23/2017
GlycoMimetics (GLYC) Stock Takes Off on Positive Phase II Leukemia Data, Breakthrough Tag     5/18/2017
4 Fatal Deaths in Seattle Genetics (SGEN)' Early-Stage Trials of AML Drug     12/30/2016
New York’s Cellectis (ALCLS) Looks to 2017 for Clinical Trials of AML Treatment     12/16/2016
FDA Places Clinical Hold on AML Drug Co-Developed by Johnson & Johnson (JNJ) and Genmab A/S (GEN.CO)     9/20/2016
Another Celgene (CELG) Bet Pays Off as Agios (AGIO) Eyes Early Approval of Leukemia Drug     9/8/2016
FDA Berates Celator Pharma (CPXX) for Pushing Unapproved Leukemia Drug to Doctors     9/8/2016
MEI Pharma (MSHL)'s Pracinostat Called a Breakthrough By the FDA     8/1/2016
Ultragenyx (RARE) Rising on Phase III Acute Myeloid Leukemia Data     7/15/2016
Celator Pharma (CPXX) Jumps on Breakthrough Therapy Win for Lead Cancer Drug     5/19/2016
3 Biotechs Getting Another Shot After Failed Trials     4/7/2016

News from Around the Web
Novartis AG (NVS)' Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?     8/31/2017
While Amgen (AMGN)-Size Biotechs Run Into Trouble, These Are The Biotechs With The Most Promising Pipelines     6/19/2017
Less Is More With Acute Myeloid Leukemia Drug, Erasmus University Medical Center Study     3/17/2011
Mutations in Single Gene Predict Poor Outcomes in Adult Leukemia; Discovery May Guide Treatment for Acute Myeloid Leukemia, Washington University Study     11/11/2010
Protein That Predicts Prognosis Of Leukemia Patients May Also Be A Therapeutic Target, Whitehead Institute and Children's Hospital Boston Reveals     7/12/2010
Umbilical Cord Best Treatment for Childhood Leukaemia     6/8/2007
Leukemia Drug Turns Mini-Molecules Up, Cancer Genes Down     3/1/2007
Researchers Develop New Strategy For The Treatment Of CML     1/18/2007
Role For Proteomics In Identifying Hematologic Malignancies     1/11/2007
Study Identifies Molecular Process Underlying Leukemia     8/22/2006
Cytoplasmic Location Of Shuttling Protein Often Seen With AML     1/20/2005
Perpetual AML Can Arise From Rare Leukemic Stem Cell     6/1/2004
Gene Expression Profiling Yields Prognostic Information For AML Patients     4/14/2004

Press Releases
Phase 1 Data For Flotetuzumab, MacroGenics (MGNX)’ CD123 X CD3 DART Molecule, Presented At ESMO Congress 2017     9/11/2017
Mitsubishi Tanabe Release: Comprehensive Edaravone Clinical Program Data Published As Supplement To Amyotrophic Lateral Sclerosis And Frontotemporal Degeneration Journal     9/7/2017
The Leukemia & Lymphoma Society Release: FDA Approval Of Targeted Therapy For Acute Myeloid Leukemia Is A Significant Advance For Deadly Blood Cancer     9/5/2017
Cellerant Therapeutics, Inc. Awarded $6.86 Million Grant From California Institute For Regenerative Medicine To Support Development Of Novel Antibody-Drug Conjugate For AML     8/22/2017
Syros Pharma Receives FDA Orphan Drug Designation For SY-1425 For Treatment Of AML     8/21/2017
Selvita And The Leukemia & Lymphoma Society Announce Partnership To Advance SEL120 Into Phase I For AML Patients     8/8/2017
Jazz Pharma (JAZZ) Vyxeos Scores FDA Approval in Two AML Types     8/3/2017
Helsinn And MEI Pharma (MEIP) Announce First Patient Dosed In Pivotal Phase III Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia     8/2/2017
Mateon Therapeutics (MATN) Announces Positive Initial Data From Fifth Cohort Of Phase Ib Study Of Oxi4503 In Relapsed/Refractory AML     7/31/2017
TrovaGene (TROV) Announces FDA Approval Of IND For Phase Ib/II Trial Of PCM-075 In Patients With Acute Myeloid Leukemia     7/27/2017
Syros Pharma Publishes Foundational Data Supporting Ongoing Phase II Clinical Trial Of SY-1425 For Genomically Defined AML And MDS Patients     7/21/2017
Novartis AG (NVS) Receives Positive CHMP Opinion For Rydapt (Midostaurin) For Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) And Three Types Of Advanced Systemic Mastocytosis (SM)     7/21/2017
U.S. FDA Grants Orphan-Drug Designation To Astellas (ALPMY) For Development Of FLT3 Inhibitor Gilteritinib In Acute Myeloid Leukemia     7/20/2017
Imago Biosciences Doses First Patients In The Phase IIa Portion Of The Study Of IMG-7289 In Acute Myeloid Leukemia And Myelodysplastic Syndrome     7/19/2017
Actinium (ATNM.OB) To Host Webinar Focused On Actimab-A And Recent Developments Related To CD33 Targeted AML Therapies On July 13, 2017 At 8:00 Am ET     7/13/2017

//-->